Sorry Rappers, page-71

I sold my holding at 10.5c yesterday, but forgot to change my position.

I'm still absolutely on board with the technology.

However I'm now more cautious about the product:
1) It has to be made more robust in real-world environments. I wonder if the MSF improvements were included in the USA trial software.

2) We've handed a 6-month catch-up chance to competing offers. I know we have IP over this algorithm. But data science students and nerds do this kind of stuff for a hobby! Have a look at some of the data sets over at kaggle.com. They have play and challenge datasets including medical images and other data with corresponding disease conditions where anybody can have a play at tweaking any of the hundreds of learning algorithms, or developing new ones of their own. Our existing relationships with medical organisations will prove critical in resisting the competition.

I'll be keeping tabs on the situation. Depending on the landscape I'll probably have another punt on RAP sometime late in the calendar year.